Cancer-Focused Clinical Research as a Care Option Advances with Sarah Cannon Research Inst. & American Oncology Network Partnership

Cancer-Focused Clinical Research as a Care Option Advances with Sarah Cannon Research Inst. & American Oncology Network Partnership

American Oncology Network, LLC (AON) represents an alliance of physicians and healthcare leaders dedicated to partnering to ensure long-term success of community oncology across America. As with much of cancer care, research becomes in many cases a care option and, consequently, partnerships such as the one recently announced between AON and cancer research giant Sarah Cannon Research Institute (SCRI) the research arm of HCA Healthcare signal important trends for industry observers. Most recently, the two cancer healthcare players, one focusing on care and the other on clinical trials, shared the addition of an AON partner practice called Zangmeister Cancer Clinic in Columbus, Ohio; Hematology/Oncology Clinic in Baton Rouge, LA (division of American Oncology Partners); and Messino Cancer Centers of Asheville, NC: both partner practices of AON, they also become research sites under the partnership. This means that people diagnosed with cancer in places such as Baton Rouge and Asheville, NC, get access to the most advanced cancer focused clinical trials. In some cases, this can be the difference of life and death for cancer patients.

TrialSite offers a brief breakdown of this announcement to the TrialSite Community.

How big is AON now?

AON is currently comprised of an expanding network of partner practices across 16 states. AON practices offer in-house laboratory, pathology and oral pharmacy services all under one roof so that patients can receive the care they need in one location.

Does it help patients to combine cancer care and research?

Yes. Research has shown that having easy and convenient access to expert physician care and a comprehensive range of treatments and support services close to home is vital to a patient’s well-being. By collaborating with Sarah Cannon Research Institute, which is a global leader in offering community-based clinical trials, AON is expanding opportunities for patients to participate in cutting-edge cancer research, while reducing the need to drive long distances or travel out of state for care.

Why do cancer centers such as Zangmesiter sign up for partnership with Sarah Cannon?

So the practice can also offer its patients the latest cancer trials when appropriate.

But do these cancer centers have the infrastructure to conduct studies?

In this partnership SCRI, with deep industry domain expertise, provides the support for the study.

Where will studies be held for Zangmeister’s oncology?

They will now offer clinical trials at their oncology services at their Columbus, Ohio cancer center.

Does cancer care continue to become more precision-based, targeted to the individual?

Yes, this is due to a number of factors and forces from advancements in therapies to biomarker technology. So for example at Zangmeister’s oncology services advanced cancer care treatments are “customized for each patient so they can achieve the best possible outcome.”

What are the providers at Zangmeister Medical in Columbus?

Dr. Tarek Chidiac, Dr. Patrick Elwood, Dr. Mark Knapp, Dr. Jeanna Knoble, Dr. Sameh Mikhail, Dr. Timothy Moore, Dr. Taral Patel, Dr. Jorge Rios, Dr. Mark Segal, Dr. Kothai Sundaram, Dr. Emily Whitman, Dr. Jeffrey Zangmeister and Gynecologic Oncologist Dr. Luis Vaccarello.

How does the partnership with Sarah Cannon help the oncologists?

According to AON CEO Todd Schonherz, “The physicians at Zangmeister Cancer benefit from this partnership with Sarah Cannon Research Institute in a number of ways such as expanding access to a range of innovative research trials within a community setting, ultimately matching patients with possibly life-saving experimental treatments.

Is Sarah Cannon Research Institute the first to pioneer community-based oncology drug development?

Yes.

Is Sarah Cannon Research Institute a global leader in phase 1 cancer research?

Yes.  They have grown to become a global leader in early phase research, conducting more than 500 first-in-human studies to date. Through its efforts to advance therapies for patients, Sarah Cannon Research Institute has been a clinical trial leader in the majority of approved cancer therapies over the last decade and enrolls thousands of patients on clinical trials annually throughout its network of strategic research sites.

American Oncology Network LLC

American Oncology Network, LLC (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success of community oncology. Launched in 2018, the rapidly expanding AON network currently represents 92 physicians and 62 nurse practitioners and physician assistants practicing across 16 states. The executive management team of AON encompasses more than three decades of oncology practice management experience, enabling physicians to focus on what matters most – providing the highest quality care for patients.

The organization provides unique and comprehensive protocols for managing administrative procedures and enhancing ancillary services for its affiliates. AON is able to aggregate volume and attain economies of scale, as it guides its member physicians and practices through the transition to value-based reimbursement models that improve the patient experience and help to reduce the per-capita cost of cancer care.

AON also provides a unique model of physician led, community-based oncology management. With services such as a centralized specialty pharmacy, diagnostics, pathology, fully integrated electronic medical records, a care management team and a variety of financial assistance programs, an alliance with AON ensures that patients’ experiences will be at the very pinnacle of cancer.      

Sarah Cannon Research Institute

Sarah Cannon Research Institute is the research arm of HCA Healthcare’s Cancer Institute, Sarah Cannon. Focused on advancing therapies for patients, it is one of the world’s leading clinical research organizations conducting community-based clinical trials throughout the United States and United Kingdom. A leader in drug development, Sarah Cannon has led more than 500 first-in-human clinical trials since its inception in 1993, and has been a clinical trial leader in the majority of approved cancer therapies over the last 10 years. Additionally, Sarah Cannon offers management, regulatory, and other research support services for drug development and industry sponsors as well as strategic investigator sites through its contract research organization (CRO), Sarah Cannon Development Innovations.

Responses